

type of report	Current report
number	3/2014
company	PHARMENA

Share capital increase of Cortria Corporation

The Management Board of PHARMENA S.A. informs that on 5th February 2014, the Issuer increased share capital of subsidiary company Cortria Corporation by 1,500,000 USD (through the issue of 15,000 new shares). The share capital increase is financed from the Issuer's own funds obtained from the issue of series D shares.

The funds from the share capital increase will be allocated to further financing of phase II clinical trials of innovative anti-atherosclerosis medicinal product (1-MNA).

Cortria Corporation is a private pharmaceutical company with registered headquarters in Boston, Massachusetts, USA, which conducts clinical trials focusing on developing safe and well-tolerated medicinal products for the treatment of cardiovascular diseases, particularly atherosclerosis.

The information is made public due to the fact that the goal of share capital increase of Cortria Corporation is to finance phase II clinical trials of innovative anti-atherosclerosis medicinal product. According to the Management Board of PHARMENA S.A., this increases the possibility of commercialisation of the project. Potential revenue resulting from the commercialisation of anti-atherosclerosis medicinal product may have significant influence on the financial and economic situation of Issuer's Capital Group.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1)".

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wiczorkowska - Vice President of the Board